Ravi Thadhani, MD, MPH
Ravi Thadhani, MD, MPH, is the executive vice president for health affairs (EVPHA) of Emory University, executive director of Emory’s Woodruff Health Sciences Center (WHSC), and vice chair of the Emory Healthcare Board of Directors.
As EVPHA and executive director of the WHSC, Thadhani oversees Emory’s renowned academic health sciences enterprise focused on advancing research, training, and health-care delivery innovation. The Woodruff Health Sciences Center includes Emory’s schools of medicine, public health and nursing; Winship Cancer Institute; Emory National Primate Research Center; Emory Global Health Institute; Goizueta Institute @ Emory Brain Health; Emory Global Diabetes Research Center; and Emory Healthcare.
As vice chair of the Emory Healthcare board, Thadhani provides oversight of Emory Healthcare’s CEO and leadership team, ensuring the delivery of high-quality, patient-centered care focused on supporting the health and well-being of patients around the state. Emory Healthcare, with more than 24,000 employees, 11 hospital campuses and 425 locations, is the most comprehensive academic health system in Georgia.
Thadhani most recently served as chief academic officer and dean for faculty affairs for Mass General Brigham and professor of medicine at Harvard Medical School, both in Boston, Massachusetts. At Mass General Brigham, he was a member of the executive leadership team and oversaw graduate medical education, professional development, and a $2.3 billion research enterprise. Previously, Thadhani served as vice dean of research and graduate research education at Cedars-Sinai Medical Center in Los Angeles (2017-2019), associate director of research at Mass General Brigham (2012-2017), and chief of nephrology at Massachusetts General Hospital (2013-2017).
With more than 30 years as a general and specialized internal medicine physician, Thadhani has extensive experience in patient care, research, and clinical trials. He led a successful research lab with continuous federal funding for more than 25 years, with a focus on kidney disease and developing diagnostics and therapeutics for patients with preeclampsia. He and his colleagues developed the first FDA approved test for preeclampsia (May 2023), and he is now working on a therapy for this devastating condition.
He is the author or co-author of more than 300 scientific manuscripts and has published in top-tier journals, including the New England Journal of Medicine, Lancet, and Journal of the American Medical Association. Thadhani has been inducted into several honor societies, including the American Society for Clinical Investigation, Association of American Physicians, American Epidemiological Society, and the American Clinical and Climatological Association.
A recipient of several distinguished national awards, Thadhani has an extensive track record of recruiting and mentoring women and underrepresented staff, trainees, and faculty. He has been honored with the Harold Amos Faculty Diversity Award from Harvard Medical School, the Alumni Award of Merit from the Harvard T.H. Chan School of Public Health, and the John P. Peters Award from the American Society of Nephrology.
Back to Board of Directors and Officers